Specific Biologics Inc.'s (SBI) mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body.
We are actively developing a platform technology consisting of a dual-cleaving nuclease that can be safely delivered to cells for the treatment of various genetic diseases. This technology is designed to better exploit the cell's naturally occurring DNA repair pathways through enhanced repair or predictable deletions.
Dualase is a platform gene editing technology that cuts DNA twice and leaves non-compatible DNA ends.
Other gene editors leave compatible DNA ends when they cut DNA. When a cell repairs compatible ends it leads to random insertions or deletions or a low frequency of repair.
Depending on the presence or absence of template DNA, the cell may introduce defined length deletions (no template) or increase the frequency of repair (with template).
Defined Length Deletions & Increased Repair Allow Targeting of Genetic Diseases That Could Not Be Targeted Before.
Studies in progress across a broad range of indications demonstrating the breadth of the Dualase platform
We are building our team of gene editing experts at our site located in the MaRS Centre in Toronto. Join our passionate team turning great science into therapeutics to help improve the lives of patients suffering from serious diseases. Please find out more about our open positions below:
SBI is interested in licensing compelling technologies in the gene editing field that improve nuclease function or delivery to somatic cells. Please contact us below if your technology might be a good fit.
SBI knows that a team effort accelerates research far faster than any one group can achieve alone. In this spirit, please contact us below for potential academic or industrial partnerships, collaborations or co-developments in the gene editing field.
Specific Biologics is a resident of JLABS @ Toronto. Located in a vibrant life sciences hub with access to top-tier talent from regional colleges and universities.
Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.
Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations
Specific Biologics Inc. Announces Therapeutic Development Award from the Cystic Fibrosis Foundation
Copyright © 2023 Specific Biologics Inc. - All Rights Reserved.